Page 27 - Read Online

Page 14 of 16 Chen et al. Hepatoma Res 2018;4:72 I http://dx.doi.org/10.20517/2394-5079.2018.103

study of 1,401 patients across 3 decades. Hepatol Commun 2017;1:564-71.
7. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
8. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular
carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
9. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, et al. JSH consensus-based clinical practice guidelines for the management of
hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014;3:458-68.
10. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, et al. EASL clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol 2018;69:182-236.
11. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol
2004;130:417-22.
12. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China.
J Med Screen 2003;10:204-9.
13. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A
randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987-97.
14. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, et al. Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with
chronic viral hepatitis: a randomized study in community. Am J Gastroenterol 2013;108:416-24.
15. Poustchi H, Farrell GC, Strasser SI, Lee AU, Mccaughan GW, et al. Feasibility of conducting a randomized control trial for liver cancer
screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 2011;54:1998-2004.
16. Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: information to
support informed choices. Hepatology 2017;66:1546-55.
17. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, et al. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol 2012;56:908-43.
18. Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the
prognosis of patients? Cancer J 2004;10:317-25.
19. Nusbaum JD, Smirniotopoulos J, Wright HC, Dash C, Parpia T, et al. The effect of hepatocellular carcinoma surveillance in an urban
population with liver cirrhosis. J Clin Gastroenterol 2015;49:e91-5.
20. Oeda S, Iwane S, Takasaki M, Furukawa NE, Otsuka T, et al. Optimal follow-up of patients with viral hepatitis improves the detection of
early-stage hepatocellular carcinoma and the prognosis of survival. Intern Med 2016;55:2749-58.
21. Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, et al. Hepatocellular carcinoma screening associated with early tumor detection and
improved survival among patients with cirrhosis in the US. Am J Med 2017;130:1099-106.e1.
22. Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, et al. Improved survival in patients with viral hepatitis-induced hepatocellular
carcinoma undergoing recommended abdominal ultrasound surveillance in Ontario: a population-based retrospective cohort study. PLoS
One 2015;10:1-18.
23. Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with
hepatocellular carcinoma: a nationwide cohort study. Gut 2016;65:693-701.
24. Trevisani F, Cantarini MC, Labate AMM, De Notariis S, Rapaccini G, et al. Surveillance for hepatocellular carcinoma in elderly italian
patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004;99:1470-6.
25. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, et al. Semiannual and annual surveillance of cirrhotic patients for
hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44.
26. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with
chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
27. Ungtrakul T, Mahidol C, Chun-On P, Laohapand C, Siripongsakun S, et al. Hepatocellular carcinoma screening and surveillance in 2293
chronic hepatitis B patients in an endemic area. World J Gastroenterol 2016;22:7806-12.
28. Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma
in Taiwan. Hepatology 2014;59:1840-9.
29. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in
patients with cirrhosis. Hepatology 2016;65:1196-205.
30. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with
Child-Pugh class A cirrhosis. Am J Med 1996;101:422-34.
31. Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014;28:783-93.
32. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin
Mol Hepatol 2016;22:7-17.
33. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular
carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.e1.
34. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transplant
2018;24:1171-7.
35. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed
tomography - a randomised study. Aliment Pharmacol Ther 2013;38:303-12.
36. Kim SY, An J, Lim YS, Han S, Lee JY, et al. MRI With liver-specific contrast for surveillance of patients with cirrhosis at high risk of
hepatocellular carcinoma. JAMA Oncol 2017;3:456.
37. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay
predicts early detection of hepatocellular carcinoma. J Gastroenterol 2014;49:555-63.